What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Drug: JBI-778 Oral capsule Strengths: 20 mg, 100 mg, 250 mg Starting dose: 40 mg daily Continuous once-daily administration in 21-day cycles”In the company’s words, NCT07751744 on ClinicalTrials.gov
- Tested for
- Brain Metastases From Solid Tumors, Leptomeningeal Disease, High Grade Glioma (HGG), Glioblastoma (GBM), NSCLC Patients With EGFR Activating Mutation, Adenoid Cystic Carcinoma Metastatic, Adenoid Cystic Carcinoma of the Head and Neck
- Main trialPhase 1/2
- “This is a Phase 1/2, multicenter, open-label, dose-escalation and dose-expansion study evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), cerebrospinal fluid penetration, and preliminary antitumor activity of orally administered JBI-778, a selective PRMT5 inhibitor, in patients with brain metastases, leptomeningeal disease, or recurrent high-grade glioma. The study consists of a dose-escalation phase to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), followed by expansion cohorts to evaluate preliminary efficacy at the RP2D.”In the company’s words, NCT07751744 on ClinicalTrials.gov
Other drugs for Brain Metastases From Solid Tumors
- Floretyrosine FTelix Pharmaceuticals (Innovations) Pty Limited · Phase 3
- 131I-IPATelix Pharmaceuticals (Innovations) Pty Limited · Phase 3
- HBI-8000HUYABIO International, LLC. · Phase 3
- Trastuzumab deruxtecanDaiichi Sankyo · AstraZeneca · Phase 3
- Allogeneic genetically modified gamma-delta T cellsIn8bio Inc. · Phase 1/2
- Autologous genetically modified gamma-delta T cellsIn8bio Inc. · Phase 1/2
Coming up2
- Mar 2028Phase 1 trial completes · ClinicalTrials.gov
- 31 Mar 2030Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Not yet recruiting | 31 Mar 2030 | Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma | |
| Phase 1Recruiting | Mar 2028 | First in Human Multicenter Open Name Dose-increase, Consolidation Method to Study Safety Drug-level in Blood & Drug Metabolism Clinical Activity of Oral JBI-778 in Lung Cancer Patients With, Without Brain Metastasis IDH Mutated WHO Grade 3,4 Recurrent Glioma, Salivary Glands Tumor |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026